Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.

Key facts

Study ID

NCT05074498

Run by

TrueBinding, Inc.

People needed

154

Starts

2021-10-08

Expected to finish

2022-10-13

Last updated by the study team

2023-11-18

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Body weight of ≥ 50 kilograms (kg) and body mass index (BMI) between 18 and 35 kg/meters squared (m\^2), inclusive
• Mini-Mental State Examination (MMSE) score of 24 or less
• Must be ambulatory
• Clinical diagnosis of Alzheimer's Disease (AD) consistent with the following:
• Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
• Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Criteria for Major Neurocognitive Disorder (previously dementia)
• Participants or caregiver has the ability to understand the purpose and risks of the study and provide signed and dated informed consent which includes compliance with the requirements and restrictions listed in the inform consent form (ICF) and in this protocol. Participants whose caregiver signs the informed consent must provide their assent.

You may not qualify if…

• Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the participant's dementia (e.g., medication use, vitamin B12 deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, diffuse Lewy body disease, head trauma)
• History within the past 6 months or evidence of clinically significant psychiatric illness (e.g., major depression, schizophrenia, or bipolar affective disorder)
• Diagnosis of a dementia-related central nervous system (CNS) disease other than AD (e.g., Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)
• Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening magnetic resonance imaging (MRI), in the opinion of the investigator
• Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to screening, and/or participation in any other clinical study involving experimental medications for AD within the 60 days (or 5 half lives, whichever is longer) prior to screening

Where it is running

• Clinical Trial Site — Garden Grove, California, United States
• Clinical Trial Site — San Diego, California, United States
• Clinical Trial Site — Delray Beach, Florida, United States
• Clinical Trial Site — Lady Lake, Florida, United States
• Clinical Trial Site #1 — Maitland, Florida, United States
• Clinical Trial Site — Maitland, Florida, United States
• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Stuart, Florida, United States
• Clinical Trial Site — West Palm Beach, Florida, United States
• Clinical Trial Site — Winter Park, Florida, United States
• Clinical Trial Site — Winter Park, Florida, United States
• Clinical Trial Site — Decatur, Georgia, United States
• Clinical Trial Site — Matthews, North Carolina, United States
• Clinical Trial Site — DeSoto, Texas, United States
• Clinical Trial Site — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.